Plain-English translation of NCT07831824 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new imaging agent called [68Ga]-LNTH2401 combined with PET/CT scanning to help doctors find prostate cancer more accurately. The study has two phases: first, researchers will figure out the best dose and timing for the scan, and then they'll test how well it actually detects cancer in men with newly diagnosed aggressive prostate cancer or recurrent disease.
Current imaging methods don't always reliably detect prostate cancer spread to lymph nodes and other parts of the body. This trial aims to see if this new imaging medication can give doctors a clearer picture of where cancer has spread, which would help guide surgical planning and treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive an injection of the new imaging medication and then undergo PET/CT imaging scans. Depending on which phase of the trial you enter, you may have one imaging session or multiple scans on the same day so researchers can determine the best dose and timing. The study involves visits to a medical imaging center, and researchers will compare your scan results to surgical findings or other imaging to see how accurate the new method is.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States